 Connection
Michael Bristow to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Michael Bristow has written about Clinical Trials, Phase II as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.337 |
|
|
|
-
Carroll IA, Piccini JP, Steinberg BA, Tzou WS, Richards JC, DeMets DL, Bristow MR. Symptoms Burden as a Clinical Outcomes Assessment in Heart?Failure Patients With Atrial Fibrillation. JACC Heart Fail. 2025 Apr; 13(4):573-585.
Score: 0.232
-
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005 Dec; 11(9):659-69.
Score: 0.062
-
Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000 Aug; 36(2):501-8.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|